Compare TLYS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | GLTO |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.2M | 54.5M |
| IPO Year | 2012 | 2020 |
| Metric | TLYS | GLTO |
|---|---|---|
| Price | $1.69 | $24.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.25 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 83.1K | 51.8K |
| Earning Date | 12-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $545,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $2.01 |
| 52 Week High | $4.60 | $38.33 |
| Indicator | TLYS | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 53.37 |
| Support Level | $1.58 | $19.42 |
| Resistance Level | $1.86 | $24.99 |
| Average True Range (ATR) | 0.14 | 2.89 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 22.66 | 35.78 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.